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Background: In patientswith fibrosing interstitial lungdisease (fILD), gastroesophageal reflux (GER) is
highly prevalent, perhaps becauseof theeffects of lungfibrosis on altering intrathoracic pressure, dia-
phragm morphology and lower esophageal sphincter (LES) function. For unclear reasons, obstructive
sleep apnea (OSA) is also highly prevalent among patients with fILD. We conducted this study to test
our hypothesis that, in patients with fILD, OSA would exacerbate diaphragm/LES dysfunction and
increase the propensity fordand severity ofe GER.
Methods: Weidentifiedpatientswith fILDwhounderwent screeningpolysomnogramandpHorpH/im-
pedence probe at our center during the same week. We examined the association between OSA and
GER and used logistic regression to determine independent predictors of OSA or GER.
Results: In 54 included subjects, neither OSA (dichotomous) nor apnea hypopnea index (continuous)
predicted the presence of GER. Regardless of body position (upright, recumbent), GER was no more
frequentor severeamongsubjectswithOSAvs. thosewithoutOSA.Subjectswith idiopathicpulmonary
fibrosis (IPF) had an odds of GER nearly seven-fold greater than subjectswith other forms of fILD (odds
ratioZ 6.84, 95% confidence interval 1.36e34.43, pZ 0.02). For the entire cohort and the subgroup
with IPF, there was no correlation between pulmonary physiology and GER.
Conclusions: In fILD,OSAdoesnotappeartopromoteGER.Research isneededtodetermine ifcompen-
satorymechanisms emanating from the crural diaphragmpreventGER in fILD patientswithOSA and to
sort out whether GER has a role in the pathogenesis of certain forms of fILD.
ª 2012 Elsevier Ltd. All rights reserved.398 1621; fax: þ1 303 398 1040.
.J. Swigris).
2 Elsevier Ltd. All rights reserved.
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predicted for gender, age, and height (e.g., FVC% and DLCOFibrosing interstitial lung disease (fILD), regardless of
cause, tends to be a progressive condition, to respond
poorly to medicinal therapy, and to shorten the lives of
patients afflicted with it. One of the most common forms of
fILD, idiopathic pulmonary fibrosis (IPF), is particularly
lethal, with a median survival around three years from the
time of diagnosis.1 For reasons that have yet to be eluci-
dated, obstructive sleep apnea (OSA) appears to be
exceedingly common in patients with IPF(2)dso does
gastroesophageal reflux disease (GERD).3 In fact, investi-
gators have theorized that GERD or more specifically
occult, repetitive acidic microaspirationdplays a key role
in the pathogenesis of IPF. A competing hypothesis is that
microaspiration has nothing to do with IPF, and lung fibrosis
itselfdby altering intrathoracic pressure and resultant
morphologic or mechanistic effects on the diaphragm’s
esophageal hiatus and the lower esophageal sphincter
(LES)dmakes GERD more likely in patients with fILD.
The estimated prevalence of obstructive sleep apnea (OSA)
in middle-aged U.S. adults is approximately 2e4%.4,5 Compli-
cations of OSA include systemic and pulmonary hypertension,
stroke, mood disturbance, and cardiac dysrhythmia.6 Although
the debate is long-standing, many investigators also believe
OSA causes GERD. Specifically, respiratory effort in the face of
an obstructed upper airway creates a transdiaphragmatic
pressure differential (driven by greatly negative intrathoracic
pressure) that promotes the reflux of gastric juices into the
esophagus and possibly the larynx.7,8 Other investigators
contend the link between OSA and GERD is more circuitous:
obesity and hiatal hernia are the common denominators con-
founding the apparent association between the two.9,10
We conducted this study to examine the putative link
between OSA and GERD in patients with non-connective
tissue disease-related fILD by testing the following two
hypotheses: 1) given the theory on lung fibrosis altering the
diaphragm/LES apparatus, among patients with fILD, the
presence of OSA greatly promotes esophageal reflux; and 2)
there is an association between fILD severity (based on
pulmonary physiology) and the severity of GERD.Methods
Subjects
fILD
Potential subjects included patients with fILD first evalu-
ated at National Jewish Health between January 2006 and
March 2011 and who underwent both split-night, screening
polysomnogram (PSG) and either 24-h esophageal pH or pH/
impedence probe at our center as part of their ILD evalu-
ation. The decision to perform the PSG and pH probe was
made by the evaluating physicians, of whom certain
considered PSG and pH probe components of a standard ILD
evaluation. The PSG and probe were done during the same
week but not the same night. Pulmonary physiology data
were taken from tests performed during the week of the
PSG and pH probe testing, and results for forced vital
capacity (FVC) and diffusing capacity of the lung for carbonmonoxide (DLCO) are expressed as percentages of the value
% respectively).
Subjects were identified via ICD-9 codes, and the diag-
nosis of fILD was confirmed by review of the chart and high-
resolution chest computed tomography (HRCT) scan as well
as surgical lung biopsy (SLB) specimens where available. In
the absence of a SLB, fILD was considered present when
slices from an HRCT scan showed traction bronchiectasis
along with reticular opacities and/or honeycombing in the
face of restrictive pulmonary physiology and/or reduced
DLCO. A diagnosis of IPF was rendered in accord with
consensus guidelines acceptable for the time.1 A diagnosis
of fibrotic non-specific interstitial pneumonia (fNSIP) was
rendered either when SLB specimens confirmed the pres-
ence of a fNSIP-pattern or, in the absence of a SLB, when
the HRCT pattern suggested fNSIP as the underlying histo-
logic pattern (i.e., when the radiologist identified lower
lobe predominant fILD that did not fit a classic UIP-
pattern). To avoid issues related to esophageal dysfunc-
tion stemming from connective tissue disease (CTD),
patients with CTD were excluded.
Controls
We used the control group only as internal validation for
certain analyses performed in subjects with fILD. The
control group was formed by identifying patients with
asthma first evaluated at National Jewish Health over the
same time period and who underwent both split-night,
screening PSG and either 24-h esophageal pH or pH/impe-
dence probe at our center as part of their asthma evalua-
tion. Patients with asthma were selected as controls for the
following reasons: 1) they have lung disease (i.e., their
lungs are not normal); and 2) because of the institution-
wide, perceived relationship between GERD and asthma,
they were the patient group most likely to have undergone
both PSG and pH probe at our center.Definitions for OSA and GERD
All sleep studies were performed in the Sleep Laboratory at
National Jewish Health. In our lab, apneas and hypopneas
are defined as an absence of flow (apnea) or reduction in
flow by 30% (hypopnea) from baseline for 10 s accompanied
by a fall in SpO2 of 4% or greater. Supplemental oxygen was
started if the saturation was less than 90% on room air when
awake or with desaturation events when asleep. OSA was
defined by an apnea hypopnea index (AHI) greater than or
equal to five events per hour. The pH probes used were
single-use, dual-channel pH or impedence/pH probes by
Sandhill Scientific (Sandhill Scientific, Highlands Ranch,
CO). The probe was inserted nasally such that the distal
channel was located 5 cm above the lower esophageal
sphincter (LES), and the proximal channel was located
20 cm above the LES. Proximal acidic GERD was considered
present if pH at the proximal channel reading was <4 for 
0.9% of the total time; <4 for 1.2% of the upright time; or
<4 for >0% of the recumbent time. Distal acidic GERD was
considered present if the pH at the distal channel was <4
for 4.2% of the total time (if non-medicated) or 1.3% of
the total time (if medicated); <4 for 6.3% of the upright
Table 1 Baseline characteristics of subjects with fILD.
fILD N Z 54
Demographics
Age in years 69.2  7.0 69.0 (65.0e75.0)
Male, % 65
BMI 30.4  6.9 29.9 (25.8e33.1)
Lung disease data
FVC% 64.0  15.9 64.0 (52.0e74.0)
DLCO% 43.4  16.5 44.0 (29.0e55.0)
ILD Dx, N
Asbestosis 2
cHP 3
fFIP 6
fNSIP 19
IPF 22
fSarcoidosis 1
ILD Tx, N
None 48
Azathioprine 4
Mycophenolate mofetil 1
Cyclophosphamide 1
On prednisone, % 25
Supplemental oxygen, N
24 h 17
Exertion and sleep 4
None 33
Sleep data
Has OSA
5 < AHI  15 15
15 < AHI  30 6
AHI > 30 14
AHI 23.7  31.2 10.8 (2.5e31.2)
Nadir SpO2 during PSG 77.5  8.9 79.0 (74.0e83.0)
Epworth Sleepiness
Scale (ESS)*
7.9  3.6 9.0 (5.0e10.0)
ESS > 9, %* 37
% With ESS > 9 and OSA 72
GERD data
GERD symptoms, % 17
On daily anti-reflux Tx, % 44
On PPI during pH probe, % 21
Data are mean  standard deviation, median (interquartile
range), other values are percentages or proportions;
fILDZ fibrotic interstitial lung disease; BMIZ body mass index;
FVC% Z percent predicted forced vital capacity; DLCO
%Z percent predicted diffusing capacity of the lung for carbon
monoxide; ILD Z interstitial lung disease; Dx Z diagnosis;
cHP Z chronic hypersensitivity pneumonitis; fFIP Z fibrotic
familial interstitial pneumonia; fNSIP Z fibrotic non-specific
interstitial pneumonia; Tx Z medication; OSA Z obstructive
sleep apnea; AHI Z apnea hypopnea index; *N Z 49 subjects
with fILD; PSG Z polysomnogram; SpO2 Z peripheral oxygen
saturation; ESS Z Epworth Sleepiness Scale;
GERD Z gastroesophageal reflux disease; Tx Z treatment;
PPI Z proton pump inhibitor.
Sleep and GERD in ILD 1035time (if non-medicated) or 1.5% of the upright time (if
medicated); <4 for 1.2% of the recumbent time (if non-
medicated) or 1.3% of the recumbent time (if
medicated).11
Statistical analysis
Categorical variables are reported as percentages and were
analyzed between groups by using Chi-square or Fisher’s
exact test (where appropriate). Continuous variables are
expressed as measures of central tendency and, because
they were non-normally distributed, were analyzed
between groups by using the ManneWhitney U test.
Correlations between continuous variables were analyzed
by using Spearman rank coefficients. We examined the
relationship between outcome (presence of either GERD or
OSA) and predictors in subjects with fILD by using bivariate
logistic regression analyses, in which demographic and
pulmonary physiology variables were considered candidate
predictors. We defined p < 0.05 to represent statistical
significance for each analysis, except for the correlation
and analyses of pH probe variables between subjects with
or without OSA. For these, we considered p  0.001 to
represent statistical significance, to account for multiple
comparisons. All statistical testing was performed with SAS
(SAS Inc., Cary, NC) Version 9.2. This study was approved by
the National Jewish Health Institutional Review Board.
Because of the retrospective study design, informed
consent was not required.
Results
We enrolled 54 subjects with fILD, the majority of whom
were male, and 25% were taking prednisone when the PSG
and pH probe were performed (Table 1). Among several pH
probe variables assessed, the only difference between fILD
subjects and asthma controls was the proportion in each
group with abnormal acid at the proximal electrode while
upright (fILD 56% vs. asthma 32%, pZ 0.005). Among those
same pH/impedence probe variables, none suggested worse
GERD in fILD subjects with OSA vs. those without OSA (Table
2 and Appendix Table 1). Percentage of total time, as well
as times in the upright or recumbent position, with
abnormal distal esophageal acid exposure was greater in
fILD subjects without OSA than those with OSA. In asthma
controls, none of the pH/impedence probe outcomes
differed significantly between those with vs. those without
OSA (Appendix Table 2).
Among subjects with fILD, there was no correlation
between FVC%, DLCO%, body mass index, or apnea hypo-
pnea index and any of several pH probe proximal or distal
electrode outcomes (e.g., acidic- or non-acidic reflux
episodes, time with pH < 4, etc.) (Table 3 and Appendix
Table 3). The results of bivariate logistic regression anal-
yses for GERD and OSA are displayed in Tables 4 and 5
respectively. Among several candidates, the only signifi-
cant predictor of the presence of GERD was having a fILD
diagnosis of IPF. In several multivariable models controlling
for any combination of age, male gender, DLCO%, distance
walked during a 6-min walk test, presence of OSA and nadir
SpO2 during the PSG, having a diagnosis of IPF remaineda (and the only) significant independent predictor of GERD.
The only significant predictor of OSA was nadir peripheral
oxygen saturation during the PSG.
We conducted similar analyses, including the bivariates,
correlations, and analyses of the pH/impedence probe
1036 M. Pillai et al.outcomes, for the following two subgroups: 1) fILD subjects
with IPF; 2) fILD subjects not taking anti-reflux medications
at the time of the pH probe; and for data from the pH probe
limited to recumbent body position. The results for all of
these analyses were similar to those described above.
Ninety percent of subjects with IPF had GERD; 64% had OSA;
and 50% had both GERD and OSA.Discussion
We identified 54 subjects with non-connective tissue disease-
related fILDwho underwent PSG and pH probewithin the same
week at our center between January 2006 andMarch 2011. Our
working hypothesis held that GERD, perhaps stemming from
altered intrathoracic pressure and its effects on the diaphrag-
matic esophageal hiatus and LES, would occur with greater
frequency in fILD subjects with OSA than in those without OSA.
In contrast, we observed no relationship between the presence
of OSA and the presence of GERD in subjects with fILD. Nor did
we observe any association between the severity of either fILD
or OSA and GERD severity in these subjects.
In this study, our goal was not to derive prevalence
estimates for GERD or OSA in fILD; indeed, subjects likely
underwent testing for these conditions because their
physicians strongly suspected them to be present. Rather,
we aimed to begin to explore the potentially intersecting
pathways of OSA, GERD and fILD. Other investigators have
looked at GERD and OSA separately in samples with fILD. In
1998, Tobin and co-investigators were first to assess the
association between GERD and fILD by studying 17 subjects
with biopsy-proven IPF; they identified GERD in 16 subjects,
only four of whom had GERD symptoms.12 Given those
results, they speculated that GERD may play a significant
role in the pathogenesis of IPF.
Raghu and colleagues found that 87% of 65 consecutive
IPF patients had GERD, compared with only 68% of asth-
matic controls (p Z 0.01 for the comparison).3 They also
found that 12 of 17 subjects with IPF on a proton pump
inhibitor (PPI) during the pH probe had GERD; each of the
three of our IPF subjects who took a PPI while the pH probeTable 2 Demographic, lung disease, GERD and recumbent body
on the presence of OSA.
Has OS
Demographics
Age 69.0 (6
BMI 30.0 (2
Lung disease data
FVC% 65.0 (5
DLCO% 42.5 (3
pH probe data
Any GERD 59
Recumbent body position pH probe data
% On PPI during pH Probe 21
% With Abnormal Proximal Acid Recumbent 26
% With Abnormal Distal Acid Recumbent 39
Data are median (interquartile range); BMI Z body mass index; FVC
predicted diffusing capacity of the lung for carbon monoxide; GERD Zwas in place had GERD. Like Raghu and his colleagues, we
discovered that only a minority of subjects with fILD
experienced daily GERD symptoms, and like us, they
observed no correlation between fILD severity and GERD
severity. Sweet and colleagues found GERD to be highly
prevalent in IPF patients referred for lung transplantation
evaluation,13 and those with GERD were significantly more
likely than those without GERD (65% vs. 10%, pZ 0.004) to
have LES hypotension by esophageal manometry. Their
study was not designed to answer the question of whether
lung fibrosis (and intrathoracic pressure alterations, etc.)
caused the LES hypotension, nor was it designed to assess
LES pressures during apneic events. As in the study by
Raghu and colleagues, the presence of symptoms did not
accurately predict GERD by pH probe.
In a recent publication, Lee and co-authors describe
a study in which they observed a risk of death among IPF
patients taking daily anti-reflux therapy that was less than
half that of IPF patients not taking daily anti-reflux
therapyda risk that held even after adjusting for poten-
tially influential predictor variables like FVC.14 Although
evidence of the inextricable link between fILD and GERD
continues to mount, none of the data from these hypothesis-
generating studies can inform the question of whether GERD
(or occult, repetitive microaspiration) causes fILD.
A number of researchers have examined, in patients
with IPF, sleep and sleep-related problems, including
nocturnal desaturation, tachypnea, and disrupted sleep
architecture15e19dthis work has also suggested a high
prevalence2 and probable under-recognition20 of OSA in
fILD. Like Lancaster and her colleagues,2 we found no link
between pulmonary restriction and OSA. Although they
found a weak, borderline significant relationship between
body mass index (BMI) and apnea hypopnea index(AHI)
(rZ 0.3, pZ 0.05), we observed no significant association
between the two in our subjects with fILD.
Studies on the triad of OSA, GERD and fILD are few.
Lancaster and colleagues2 did report the prevalence of
GERD among their IPF subjects with or without OSA (50% vs.
70%, p Z NS), but pH probes were not done as part of that
study, and it is unclear how or whether the diagnosis ofposition pH probe outcomes between fILD subjects stratified
A N Z 35 No OSA N Z 19 p
6.0e76.0) 69.0 (65.0e74.0) 0.76
5.1e32.3) 29.9 (25.8e34.0) 0.86
3.0e74.0) 62.0 (47.0e78.0) 0.61
1.0e55.0) 44.0 (27.0e57.0) 0.89
41 0.15
21 0.99
47 0.11
61 0.15
% Z percent predicted forced vital capacity; DLCO% Z percent
gastroesophageal reflux; PPI Z proton pump inhibitor.
Table 4 Bivariate analyses: predictors of GERD among
subjects with fILD.
Predictor Odds ratio (95% CI) p
Age 0.91 (0.80e1.03) 0.1
Male gender 3.10 (0.69e14.08) 0.1
BMI 0.98 (0.89e1.08) 0.7
FVC% 1.02 (0.97e1.06) 0.5
DLCO% 1.04 (0.98e1.10) 0.2
IPF diagnosis 6.84 (1.36e34.43) 0.02
6MWD 1.00 (0.99e1.00) 0.1
Nadir SpO2 during 6MWT 1.12 (0.87e1.45) 0.4
Daily supplemental O2 use 0.65 (0.15e2.89) 0.6
Prednisone use 3.20 (0.35e29.00) 0.3
Reported GERD symptoms 1.03 (0.10e10.55) 0.9
Daily anti-reflux therapy 3.31 (0.60e18.19) 0.2
Has OSA 0.35 (0.09e1.48) 0.2
AHI 1.00 (0.97e1.02) 0.7
RERA 0.98 (0.92e1.05) 0.6
Nadir SpO2 during PSG 1.08 (0.98e1.18) 0.1
BMIZ body mass index; FVC%Z percent predicted forced vital
capacity; DLCO%Z percent predicted diffusing capacity of the
lung for carbon monoxide; IPFZ idiopathic pulmonary fibrosis;
SpO2Z peripheral oxygen saturation; 6MWDZ distance walked
during the 6-min walk test (6MWT); GERD Z gastroesophageal
reflux disease; OSA Z obstructive sleep apnea; AHI Z apnea
hypopnea index; RERA Z respiratory event arousal index;
PSG Z polysomnogram.
Table 5 Bivariate analyses: predictors of OSA among
subjects with fILD.
Predictor Odds ratio (95% CI) p
Age 1.01 (0.92e1.12) 0.8
Male gender 1.94 (0.54e7.02) 0.3
BMI 0.96 (0.88e1.05) 0.4
FVC% 1.01 (0.98e1.05) 0.5
DLCO% 1.02 (0.98e1.06) 0.4
IPF diagnosis 0.92 (0.30e2.85) 0.9
6MWD 1.00 (0.99e1.00) 0.5
Nadir SpO2 during 6MWT 1.04 (0.83e1.31) 0.7
Daily supplemental O2 use 0.93 (0.26e3.31) 0.9
Prednisone use 0.36 (0.09e1.47) 0.2
Has GERD by pH probe 0.35 (0.09e1.48) 0.2
Daily anti-reflux therapy 0.96 (0.28e3.33) 0.9
Nadir SpO2 during PSG 0.81 (0.69e0.95) 0.009
BMIZ body mass index; FVC%Z percent predicted forced vital
capacity; DLCO%Z percent predicted diffusing capacity of the
lung for carbon monoxide; 6MWDZ distance walked during the
6 min walk test (6MWT); GERD Z gastroesophageal reflux
disease; AHI Z apnea hypopnea index; SpO2 Z peripheral
oxygen saturation; PSG Z polysomnogram.T
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Sleep and GERD in ILD 1037GERD was confirmed beyond self-report. To our surprise, in
our study, we did not find evidence that having OSA
increased the propensity for GERD in subjects with fILD. We
suspected that if, as theorized, fILD indeed alters the
morphology of the esophageal hiatus and the mechanical
function of the LESdeffects that would decrease the
1038 M. Pillai et al.natural anti-reflux barrier and make GER more likelydthen
the transdiaphragmatic pressure differentials occurring
during apneic events would have further increased GER,
and this would have been clearly seen in the pH probe data
with subjects in the recumbent position (i.e., laying down,
sleeping). However, isolating pH probe data from the
recumbent position, we observed that subjects with OSA
were no more likely than those without OSA to have
recumbent GER.
Why might this be? One reason is that diaphragm func-
tion is not limited to driving respiration. Using high-
resolution manometry, Kuribayashi and co-
investigators(10) observed non-respiratory activation of
the diaphragm during apneic episodes among their subjects
with OSA. Thus, despite a rising abdominal-thoracic pres-
sure differential, stemming from increasingly labored
breathing efforts during apneic events, GER was prevented
by equally vigorous crural diaphragm contractions that
shored-up the anti-reflux barrier. It would be interesting to
determine if a similar process occurs in patients with fILD;
the results of our study do not refute the possibility that it
does. But another study will be needed to address this
question directly. Why subjects with IPF were significantly
more likely than subjects with other fILDs to have GERD is
unclear. Perhaps the crural diaphragm-esophageal hiatus-
LES apparatus behaves differently indor is affected
differently byddifferent types of lung fibrosis. If dysfunc-
tion of the entire apparatus (or LES alone) hinges on its
proximity to fibrosis, then the usual interstitial pneumonia-
pattern of lung injury (as opposed to say upper lobe fibrosis,
as occurs in chronic hypersensitivity pneumonitis) would
seem most likely to have the greatest influence on LES
dysfunction. Obviously, this is purely speculative and would
require completion of a different study to sort out.
Our study has several limitations. The first is that the
sample size is relatively small and represents a highly-
selected and very small fraction of fILD evaluated at our
center over the study period.Wewere not able to determine
thenumber of patientswhomight havehadeither aPSGorpH
probe ordered but did not end up completing the test. In
addition, it is not possible for us to ascertain the circum-
stances within which either test was ordered. Clearly, for
certain subjects, these testswereorderedwithout regard for
a screen that suggested a low probability of disease. For
example, PSGs were ordered in 39% of subjects despite
Epworth Sleepiness Scale scores of six or lessdscores that
suggest a low probability of OSA. This reflects the practice by
some physicians at our institution of ordering a PSG and pH
probe as a routine part of the ILD evaluation. Some subjects
took anti-reflux medications during the pH probe study.
Recognizing this could influence results, particularly the
occurrence of acidic reflux events, we performed a set of
analyses after excluding those subjects, and found all the
results were similar. Because the PSG and pH probe were not
performed the same night, we were not able to directly link
the timing of apnea hypopnea and reflux events. We were
subject to referral bias, and we can not ignore the fact that
the cohort comprises a select group of patients with fILD that
may not be representative of fILD patients in the community.
However, for the purposes of this hypothesis-generating
study, we do not believe these limitations are significant.
To study OSA and GERD, we needed subjects who hadundergone tests for both conditions; when beginning to
dissect the relationship between the two conditions in this
patient group, it does notmatterwhy the testswereordered.
In summary, subjects with fILD and OSA were not more
likely to have GERD than those with fILD but no OSA. And
we observed no association between the severity of lung
fibrosis and the presence of GERD. Additional prospective
research is needed to confirm our results, to further clarify
why patients with fILD (but interestingly, not especially
those with OSA) seem to be prone to GERD, to discern
whether GERD and occult microaspiration play a role in the
pathogenesis of certain types of fILD, and to determine
whether identifying (and subsequently effectively treating)
GERD leads to improvements in survival or other meaningful
outcomes in this patient group.
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